27 31 35 36 Because primaquine-induced haemolysis is dose-dependent, 29 and because gametocytocidal efficacy may be retained with primaquine doses lower than 0.75 mg/kg, the WHO-recommended dose in its 2010 Guidelines for the Treatment of Malaria, dose-finding studies are needed urgently.
Bulaquine is currently licensed only for use in India for the radical cure of vivax malaria dosed at 25 mg/day for 5 days, but not as a gametocytocidal agent IN Plasmodium falciparum.
Longitudinal models showed the same results, with p-values<0.0001 at all post-immunization time points for each malaria vaccine dose group compared to rabies vaccine.
These T cell and Treg repertoires, responding to mosquito-allergen inflammation, and the minimal malaria antigen doses transmitted in bites, provide amply for de novo malaria-specific suppressive iTreg generation, and expansion of pre-existing, potentially cognate [233] nTregs, via Treg induction and expansion mechanisms [225] documented in the basic literature (see above Section 4-iv).
The prototypical compound TDR32750 showed potent antimalarial activity against a panel of strains of Plasmodium falciparum and significant depression of parasitaemia (>99%%) in the Plasmodium berghei mouse model of malaria when dosed intraperitoneally.
Among 23 children with cerebral malaria, a dose-response effect with use of boluses of mannitol was observed in moderately raised ICP (ICP > 20 mmHg, CPP < 50 mmHg) but not with severely raised ICP (ICP > 40 mmHg, CPP < 40 mmHg)[ 1].
A dose-response antibody effect was suggested by higher mean antibody responses in the full-dose malaria vaccine group compared to half-dose group, with these differences approaching but not reaching significance at study days 74, 90, and 180 (p = 0.050, 0.053, and 0.079, respectively).
Five participants (two each in the malaria vaccine half-dose and full-dose groups and one in the rabies vaccine group) had Grade 1 elevated ALT levels, and one participant in the malaria vaccine full-dose group had an ALT of 194 U/L on study day 30, prior to immunization.
Overall, unsolicited adverse events reported during the 31-d post immunization periods were balanced by group, with 109, 109 and 100 events reported for the malaria vaccine full-dose group, half-dose group and rabies vaccine group, respectively.
Grade 3 low platelet counts were reported for two participants in the malaria vaccine high dose group, but these were unaccompanied by any clinical signs and were determined to be false positive results from an automated cell counter caused by platelet aggregation, based on microscopic examination of the blood.
The guideline was in cartoon format and had pictorial illustrations of some common clinical features of uncomplicated malaria, the correct dose and regimen of AL according to the age of the child [Fig 1].
